Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

NCT06108479 is registered in ClinicalTrials.gov with Dragonfly Therapeutics as lead sponsor.

NCT NCT06108479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06108479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors
Lead sponsor
Dragonfly Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 28, 2023
Completion date
December 4, 2025
Enrollment
35 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor cancer, solid tumor, adult